Paradigm Biopharmaceuticals (ASX: PAR) was featured in The Armchair Analyst this morning, with the article highlighting growing market interest ahead of the upcoming Phase 3 interim analysis of our PARA_OA_012 study in knee osteoarthritis.

The article discusses the significance of the upcoming clinical catalyst and the broader investor interest surrounding the readout, which is expected within the coming weeks.

Read the full article: Can PAR score PAR in the next biotech readout?

The views expressed in the article are those of the author and are independent of Paradigm Biopharmaceuticals.